BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease
Search BioPortfolio:       
BioNews
Biotechnology, Pharmaceutical, Life Science & Medical News
Track this topic with BioWatch News Alerts: Register | Login
search help

Search Results

Documents 1-25 out of 456 found
  Current Search:  herceptin: 456     

HTML
100%
Roche bid for Genentech faces lawsuit
Roches $43.7 billion (21.8 billion) takeover of the 41 per cent of Genentech it does not already own was yesterday met with a lawsuit claiming that the deal short-changed shareholders.

Switzerlands Roche announced on Monday that it had...

The Times:  Jul 23 2008 11:25PM
Matching: herceptin
Find similar documents
HTML
100%
SWCRF Researcher Identifies Ways to Significantly Expand the Applicability of a Unique Anti-Cancer Drug
Wilson H.

Miller, Jr.

Millers research has identified how arsenic trioxide can be used in combination with other cancer-fighting drugs to significantly increase the overall anti-cancer effect.

Arsenic trioxide-based combination therapy...

Pharma Live:  Jul 23 2008 11:17PM
Matching: herceptin
Find similar documents
HTML
100%
SWCRF Researcher Identifies Ways to Significantly Expand the Applicability of a Unique Anti-Cancer Drug
Wilson H.

Miller, Jr.

Professor Department of Medicine Division of Experimental Medicine McGill University NEW YORK, July 22, 2008--Arsenic Trioxide is a drug with an amazing impact on reversing the growth of acute promyelocytic leukemia...

Pharmalive.com:  Jul 23 2008 3:22PM
Matching: herceptin
Find similar documents
HTML
100%
Roche looks to maximize Genentech potential
Roche has initiated efforts to acquire all outstanding shares in Genentech for approximately $43.7 billion, having purchased 55.9% of the company in 1990.

While Genentech has historically operated independently from its parent company, it...

Datamonitor:  Jul 23 2008 2:31PM
Matching: herceptin
Find similar documents
HTML
100%
Genentech shareholders sue over Roche bid
The suit, brought in Delaware Chancery Court, seeks to block the Swiss drugmaker's bid from going forward under its current terms.

Roche has offered to buy all outstanding shares in Genentech, its U.S.

partner, for $89 a share in cash to...

Washington Post:  Jul 23 2008 8:49PM
Matching: herceptin
Find similar documents
HTML
100%
Genentech shareholders sue over Roche bid
NEW YORK (Reuters) - A Genentech Inc investor filed a lawsuit on Wednesday over the proposed $43.7 billion buyout by majority shareholder Roche Holding AG , saying the bid is unfair and inadequate.

The suit, brought in Delaware Chancery...

Reuters via MSN Money:  Jul 23 2008 8:43PM
Matching: herceptin
Find similar documents
HTML
100%
Roche bids for remaining Genentech stake
The Swiss pharmaceutical giant Roche has offered nearly US$44 billion to acquire the 44% of biotechnology jewel Genentech that it doesn't already own.

The offer immediately raised questions about how independent the highly successful,...

Nature:  Jul 23 2008 5:11PM
Matching: herceptin
Find similar documents
HTML
100%
What Now, Genentech Investors?
AMGNBIIB CELG DNA GENZ GILD (Action Alerts PLUS PICK) Article Tools Related Articles 1 Member Recommended this article Recommend it (Editor's note: Come see Adam Feuerstein at the Money Show in San Francisco.

Adam will be speaking to...

TheStreet.com:  Jul 23 2008 4:23PM
Matching: herceptin
Find similar documents
HTML
100%
MOST READ: What Now, Genentech Investors?
AMGNBIIB CELG DNA GENZ GILD (Action Alerts PLUS PICK) Article Tools Related Articles 1 Member Recommended this article Recommend it (Editor's note: Come see Adam Feuerstein at the Money Show in San Francisco.

Adam will be speaking to...

TheStreet.com:  Jul 23 2008 1:40PM
Matching: herceptin
Find similar documents
HTML
100%
What Now, Genentech Investors?
AMGNBIIB CELG DNA GENZ GILD (Action Alerts PLUS PICK) Article Tools Related Articles Be the First Member to Recommend this article Recommend it (Editor's note: Come see Adam Feuerstein at the Money Show in San Francisco.

Adam will be...

TheStreet.com:  Jul 23 2008 12:04PM
Matching: herceptin
Find similar documents
HTML
100%
[external] What Now, Genentech Investors?
AMGNBIIB CELG DNA GENZ GILD (Action Alerts PLUS PICK) Article Tools Related Articles Be the First Member to Recommend this article Recommend it (Editor's note: Come see Adam Feuerstein at the Money Show in San Francisco.

Adam will be...

Yahoo!:  Jul 23 2008 11:46AM
Matching: herceptin
Find similar documents
HTML
100%
Roche $43.7B Genentech Offer Likely to Feel Upward Pressure
Byline: Donna Young, Washington Editor Roche Holding AG has offered $43.7 billion, or $89 per share, to buy the 44 percent it does not own already of Genentech Inc., the world's largest biotech.

If the merger is completed, Basel,...

Therapeutics Daily:  Jul 23 2008 11:22AM
Matching: herceptin
Find similar documents
HTML
100%
What Now, Genentech Investors?
AMGNBIIB CELG DNA GENZ GILD (Action Alerts PLUS PICK) Article Tools Related Articles Be the First Member to Recommend this article Recommend it (Editor's note: Come see Adam Feuerstein at the Money Show in San Francisco.

Adam will be...

TheStreet.com:  Jul 23 2008 11:19AM
Matching: herceptin
Find similar documents
HTML
100%
What Now, Genentech Investors?
When Roche eventually completes the job of DNA Where will all that money go?

The most obvious answer is right back into the other large-cap biotech firms like Celgene CELG A Mini-Genentech Spinoff?

Yes, it's probably too early to think...

TheStreet.com:  Jul 23 2008 11:05AM
Matching: herceptin
Find similar documents
HTML
100%
Roche-Genentech deal could spark worker defections
LOS ANGELES, July 22 (Reuters) - Roche Holding AG (News/Aktienkurs) 's <ROG.VX> plan to buy Genentech Inc (News) <DNA.N> runs the risk of triggering an exodus of employees who do not want to work for a huge company, including...
FinanzNachrichten.de:  Jul 23 2008 6:02AM
Matching: herceptin
Find similar documents
HTML
100%
Roche-Genentech deal could spark worker defections
LOS ANGELES, July 22 (Reuters) - Roche Holding AG's <ROG.VX&gt; plan to buy Genentech Inc <DNA.N&gt; runs the risk of triggering an exodus of employees who do not want to work for a huge company, including some who might look...
Interactive Investor International:  Jul 23 2008 5:59AM
Matching: herceptin
Find similar documents
HTML
100%
Genentech mulls offer by Roche; stocks rise
SAN FRANCISCO - Biotechnology pioneer Genentech Inc.

mulled Roche Holding's $43.7 billion offer for its remaining shares Monday as investors made clear their feelings that the Swiss pharmaceutical giant should pay considerably more.

But...

The Vacaville Reporter:  Jul 23 2008 2:38AM
Matching: herceptin
Find similar documents
HTML
100%
Roche-Genentech deal could spark worker defections
LOS ANGELES, July 22 (Reuters) - Roche Holding AG's (ROG.VX: Quote, Profile, Research) plan to buy Genentech Inc (DNA.N: Quote, Profile, Research) runs the risk of triggering an exodus of employees who do not want to work for a huge company,...
Reuters UK:  Jul 23 2008 2:01AM
Matching: herceptin
Find similar documents
HTML
100%
Roche Posts Very Good Results: Strong Market Outperformance Guidance Confirmed
Group sales increase 10% in local currencies (excluding Tamiflu pandemic sales) to 22 billion Swiss francs(+1% in Swiss francs; +18% in US dollars).

Including Tamiflu pandemic sales, Group sales rise 4% in local currencies (-4% in Swiss...

Drugs.com:  Jul 22 2008 2:28AM
Matching: herceptin
Find similar documents
HTML
100%
Roche-Genentech: A Drug Powerhouse
Just months into his new role as chief executive of Roche Holding (RHHBY), Severin Schwann is moving quickly to cement one of the most successful biotech pharmaceutical partnerships in history.

Eighteen years after taking a majority stake...

Yahoo! Singapore:  Jul 22 2008 3:54PM
Matching: herceptin
Find similar documents
HTML
100%
Roche-Genentech deal could spark worker defections
LOS ANGELES -- Roche Holding AG's plan to buy Genentech Inc runs the risk of triggering an exodus of employees who do not want to work for a huge company, including some who might look to start their own companies, industry sources have said...
Business Spectator:  Jul 22 2008 10:34PM
Matching: herceptin
Find similar documents
HTML
100%
Roche-Genentech deal could spark worker defections
LOS ANGELES (Reuters) - Roche Holding (other-otc: RHHBY.PK - news - people ) AG's plan to buy Genentech Inc (nyse: DNA - news - people ) runs the risk of triggering an exodus of employees who do not want to work for a huge company, including...
Forbes.com:  Jul 22 2008 10:18PM
Matching: herceptin
Find similar documents
HTML
100%
Roche likely to raise bid for Genentech: analysts
LOS ANGELES (Reuters) - Roche Holding AG may need to raise its $43.7 billion bid for the Genentech Inc stock that it does not already own, but an eventual deal is likely, analysts and investors said on Monday.

The Swiss drug maker already...

Clinical Lab Products:  Jul 22 2008 6:05PM
Matching: herceptin
Find similar documents
HTML
100%
Genentech shares surge on Roche's $44 billion offer
Wall Street analysts say the bid will have to go to $95 to $100 to get a deal done.

'It will get done but at a higher price,' says Christopher Raymond, Genentech analyst at Robert W.

Baird.

Lazard Capital Markets analyst Joel Sendek...

Yahoo!:  Jul 22 2008 2:41PM
Matching: herceptin
Find similar documents
HTML
100%
Genentech shares soar on Roche bid prospects
Shares of biotech leader Genentech soared 15 percent Monday on expectations that drugmaker Roche will have to raise its bid of $89 a share for the 44 percent of Genentech it doesn't already own.

Roche's $43.7 billion all-cash offer, issued...

CourierPostOnline.com:  Jul 22 2008 2:18PM
Matching: herceptin
Find similar documents

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.  See User Agreement

Send comments and feedback to:
Peter Barfoot Managing Director, BioPortfolio Ltd.
UK Tel: (+44) 1300 321501
USA Voicemail and Fax: (+1) 415 680 2472

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Wessex Barn, Dorchester Road, Frampton, Dorset, DT2 9NB, UK. No.3312883 VAT No. GB 744 6483 10

Copyright © 1997-2008 - BioPortfolio Limited.